Vallon Pharmaceuticals, Inc.

NasdaqCM:VLON Rapporto sulle azioni

Cap. di mercato: US$5.4m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Vallon Pharmaceuticals Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

-25.1%

Tasso di crescita degli utili

15.5%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore6.0%
Tasso di crescita dei ricavi-100.0%
Rendimento del capitale proprio-299.9%
Margine netton/a
Ultimo aggiornamento sui guadagni31 Dec 2022

Aggiornamenti sulle prestazioni recenti

Nessun aggiornamento

Recent updates

Vallon Pharmaceuticals reports Q2 results

Jul 28

We're Keeping An Eye On Vallon Pharmaceuticals' (NASDAQ:VLON) Cash Burn Rate

Dec 15
We're Keeping An Eye On Vallon Pharmaceuticals' (NASDAQ:VLON) Cash Burn Rate

We Think Vallon Pharmaceuticals (NASDAQ:VLON) Needs To Drive Business Growth Carefully

Aug 17
We Think Vallon Pharmaceuticals (NASDAQ:VLON) Needs To Drive Business Growth Carefully

Will Vallon Pharmaceuticals (NASDAQ:VLON) Spend Its Cash Wisely?

May 17
Will Vallon Pharmaceuticals (NASDAQ:VLON) Spend Its Cash Wisely?

Ripartizione dei ricavi e delle spese

Come Vallon Pharmaceuticals guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

NasdaqCM:VLON Ricavi, spese e utili (USD Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
31 Dec 220-761
30 Sep 220-954
30 Jun 220-954
31 Mar 220-955
31 Dec 210-945
30 Sep 210-834
30 Jun 210-725
31 Mar 210-625
31 Dec 200-514
30 Sep 200-413
30 Jun 200-413
31 Mar 200-412
31 Dec 190-312

Guadagni di qualità: VLON is currently unprofitable.

Margine di profitto in crescita: VLON is currently unprofitable.


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: VLON is unprofitable, and losses have increased over the past 5 years at a rate of 25.1% per year.

Accelerare la crescita: Unable to compare VLON's earnings growth over the past year to its 5-year average as it is currently unprofitable

Guadagni vs Settore: VLON is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.6%).


Rendimento del capitale proprio

ROE elevato: VLON has a negative Return on Equity (-299.91%), as it is currently unprofitable.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate